/SNDX
SNDX Stock - Syndax Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$20.77+2.67%
+$0.54 (+2.67%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+52.5%upside
Target: $31.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.56 – $20.98
TARGET (TP)$31.67
STOP LOSS$19.11
RISK/REWARD1:6.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$21.43
52W Low$8.58
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $23.68M | N/A | N/A | $139.71M | $1.52M |
| Gross Profit | $22.85M | N/A | N/A | $139.71M | $1.52M |
| Gross Margin | 96.5% | N/A | N/A | 100.0% | 100.0% |
| Operating Income | $-339,672,000 | $-229,954,000 | $-151,757,000 | $26.22M | $-71,423,000 |
| Net Income | $-318,758,000 | $-209,360,000 | $-149,338,000 | $24.93M | $-73,069,000 |
| Net Margin | -1346.1% | N/A | N/A | 17.8% | -4816.7% |
| EPS | $-3.73 | $-2.98 | $-2.46 | $0.48 | $-1.77 |
Company Overview
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
16
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
16 Bullish0 Neutral/Bearish
Price Targets
$36
Average Target
↑ 71.9% Upside
Now
$18
Low
$36
Average
$56
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 16th 2025 | H.C. Wainwright | Resumed | Buy | $40 |
| September 10th 2025 | Stifel | Resumed | Buy | $44 |
| September 4th 2025 | Guggenheim | Resumed | Buy | $34 |
| August 5th 2025 | BTIG Research | Reiterated | Buy | $56← $43 |
| July 10th 2025 | Goldman | Initiation | Buy | $18 |
| October 24th 2024 | UBS | Initiation | Buy | $37 |
| June 28th 2024 | Jefferies | Initiation | Buy | $37 |
| January 31st 2024 | Scotiabank | Downgrade | Sector Perform | $23← $36 |
| December 22nd 2023 | Mizuho | Initiation | Buy | $45 |
| October 25th 2023 | BofA Securities | Initiation | Buy | $29 |
| October 11th 2023 | Goldman | Initiation | Buy | $30 |
| July 27th 2023 | Scotiabank | Initiation | Sector Outperform | - |
| July 11th 2023 | Guggenheim | Initiation | Buy | $40 |
| April 17th 2023 | BTIG Research | Resumed | Buy | $34 |
| January 31st 2023 | Stifel | Initiation | Buy | $37 |
Earnings History & Surprises
SNDXBeat Rate
83%
Last 18 quarters
Avg Surprise
+40.5%
EPS vs Estimate
Beats / Misses
15/2
1 met exactly
Latest EPS
$-0.70
Q4 2025
EPS Surprise History
Q1 24
-1.0%
$-1.00vs$-0.99
Q2 24
+11.5%
$-0.85vs$-0.96
Q3 24
+12.1%
$-0.80vs$-0.91
Q4 24
+13.3%
$-0.98vs$-1.13
Q1 25
-1.9%
$-1.10vs$-1.08
Q2 25
+5.8%
$-0.98vs$-1.04
Q3 25
+17.0%
$-0.83vs$-1.00
Q4 25
+5.4%
$-0.70vs$-0.74
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.66 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.74 | $-0.70 | +5.4% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-1.00 | $-0.83 | +17.0% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-1.04 | $-0.98 | +5.8% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-1.08 | $-1.10 | -1.9% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-1.13 | $-0.98 | +13.3% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.91 | $-0.80 | +12.1% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.96 | $-0.85 | +11.5% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.99 | $-1.00 | -1.0% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.80 | $-0.73 | +8.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.73 | $-0.64 | +12.3% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.61 | $-0.59 | +3.3% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.64 | $-0.62 | +3.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.65 | $-0.58 | +10.8% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.65 | $-0.62 | +4.6% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.63 | $-0.63 | 0.0% | = MET |
Q1 2022 | Mar 1, 2022 | $0.28 | $1.81 | +546.4% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.64 | $-0.40 | +37.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.74 | $-0.44 | +40.5% | ✓ BEAT |
Latest News
Syndax Wins Best New Drug Award for Revuforj in Major Cancer Breakthrough
📈 PositiveBenzinga•Dec 12, 2025, 12:04 PM
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
📈 PositiveBenzinga•Dec 9, 2025, 01:03 PM
Syndax Presents Multiple Revuforj Revumenib Abstracts At ASH 2025 Supporting Menin Inhibition Leadership Across The Acute Leukemia Continuum
📈 PositiveBenzinga•Dec 8, 2025, 12:10 PM
Syndax Pharma Highlights Key Revuforj Presentations Spanning Acute Leukemia Treatment Continuum Presented At ASH Annual Meeting
📈 PositiveBenzinga•Dec 8, 2025, 11:52 AM
Shares of Syndax Pharmaceuticals are trading higher after Barclays maintained its Overweight rating and raised the price target from $22 to $35.
📈 PositiveBenzinga•Nov 24, 2025, 05:57 PM•Also:
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $35
📈 PositiveBenzinga•Nov 24, 2025, 02:37 PM•Also:
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $33
➖ NeutralBenzinga•Nov 12, 2025, 04:56 PM
Syndax Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS results. Also UBS and Barclays raised their respective price targets on the stock.
📈 PositiveBenzinga•Nov 4, 2025, 05:03 PM•Also:
UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38
📈 PositiveBenzinga•Nov 4, 2025, 03:55 PM
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
📈 PositiveBenzinga•Nov 4, 2025, 02:03 PM•Also:
Syndax Sees FY25 R&D Plus Selling, General And Administrative Expenses $380M-$385M Vs $370M-$390M Prior
➖ NeutralBenzinga•Nov 3, 2025, 09:04 PM
Syndax Pharmaceuticals Q3 EPS $(0.70) Beats $(0.73) Estimate, Sales $45.871M Miss $47.976M Estimate
➖ NeutralBenzinga•Nov 3, 2025, 09:03 PM
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 10:29 AM
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 09:25 AM
Syndax Pharmaceuticals Shares Move Lower Despite FDA Approval As Revuforj Rate Of Complete Remission Plus CR With Partial Hematological Recovery Was 23%, Co Reports High Rate Of Severe, Fatal Side Effects
📉 NegativeBenzinga•Oct 24, 2025, 06:29 PM
Syndax Pharmaceuticals shares are trading lower after the FDA approved Revuforj for relapsed or refractory acute myeloid leukemia with an NPM1 mutation, with a warning for potentially fatal differentiation syndrome.
📉 NegativeBenzinga•Oct 24, 2025, 06:27 PM
Syndax Pharmaceuticals Shares Resume Trade
➖ NeutralBenzinga•Oct 24, 2025, 06:20 PM
Trading Halt: Halt status updated at 2:15:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 24, 2025, 06:15 PM
FDA Approves Revumenib For Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible NPM1 Mutation
📈 PositiveBenzinga•Oct 24, 2025, 05:08 PM
Trading Halt: Halted at 12:56:17 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 24, 2025, 04:56 PM
Frequently Asked Questions about SNDX
What is SNDX's current stock price?
Syndax Pharmaceuticals, Inc. (SNDX) is currently trading at $20.77 per share. The stock has moved +2.67% today.
What is the analyst price target for SNDX?
The average analyst price target for SNDX is $31.67, based on 1 analyst.
What sector is Syndax Pharmaceuticals, Inc. in?
Syndax Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SNDX's market cap?
Syndax Pharmaceuticals, Inc. has a market capitalization of $1.80 billion, making it a small-cap company.
Does SNDX pay dividends?
No, Syndax Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
CVAC
CureVac N.V.
$4.16
Mkt Cap: $0.9B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
Explore stocks similar to SNDX for comparison